hCRLF2/hIL33/hTSLP
Nomenclature
C57BL/6JSmo-Il33tm2(hIL33)Tslptm2(hTSLP)Crlf2tm1(hCRLF2)Smoc
Cat. NO.
NM-XA-242305
Strain State
Repository Live
Model Description
Validation Data
The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice
Fig 1. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. Mice were challenged with OVA and hTSLP+hIL33 and treated with Itepekimab, Tezepelumab, or a combination. (A) Body weight over time. (B) Percentage change in body weight relative to baseline.
Fig 2. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Total inflammatory cell count in BALF. (B) Percentage of lymphocytes among total inflammatory cells. (C) Absolute lymphocytes count in BALF.
Fig 3. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Percentage of eosinophils among total inflammatory cells. (B) Absolute eosinophils count in BALF. (C) Percentage of neutrophils among total inflammatory cells. (D) Absolute neutrophils count in BALF.
Fig 4. Analysis of inflammatory cell populations in BALF. Flow cytometric quantification of inflammatory cells in BALF. (A) Percentage of macrophage among total inflammatory cells. (B) Absolute macrophage count in BALF. (C) Percentage of DC cell among total inflammatory cells. (D) Absolute DC cell count in BALF.
Fig 5. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. (A) Concentration of total serum IgE.
Fig 6. The efficacy of Itepekimab and Tezepelumab on OVA+hTSLP+hIL33-induced asthma model in hIL33/hTSLP/hCRLF2 mice. (A) Relative mRNA expression of mIL-13 in lung tissue. (B) Relative mRNA expression of mIL-4 in lung tissue. (C) Relative mRNA expression of mIL-5 in lung tissue.
Fig 7. Comprehensive histopathological assessment of lung injury. (A) Representative photographs of H&E-stained and PAS-stained lung sections.
Fig 8. Comprehensive histopathological assessment of lung injury. (A) Inflammatory cell infiltration Score. (B) Eosinophil cell infiltration Score. (C) Bronchial Goblet Cell Hyperplasia Score. (D) Airway Basement Membrane Thickening Score. (E) Total Lung Injury Score. (F)PAS Staining Score.
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
